You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for New Drug Application (NDA): 022410


✉ Email this page to a colleague

« Back to Dashboard


NDA 022410 describes SUBOXONE, which is a drug marketed by Indivior and is included in two NDAs. It is available from one supplier. There are four patents protecting this drug and three Paragraph IV challenges. Additional details are available on the SUBOXONE profile page.

The generic ingredient in SUBOXONE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
Summary for 022410
Tradename:SUBOXONE
Applicant:Indivior
Ingredient:buprenorphine hydrochloride; naloxone hydrochloride
Patents:4
Pharmacology for NDA: 022410
Suppliers and Packaging for NDA: 022410
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410 NDA INDIVIOR INC. 12496-1202 12496-1202-3 30 POUCH in 1 CARTON (12496-1202-3) / 1 FILM, SOLUBLE in 1 POUCH (12496-1202-1)
SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410 NDA INDIVIOR INC. 12496-1204 12496-1204-3 30 POUCH in 1 CARTON (12496-1204-3) / 1 FILM, SOLUBLE in 1 POUCH (12496-1204-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM;BUCCAL, SUBLINGUALStrengthEQ 2MG BASE;EQ 0.5MG BASE
Approval Date:Aug 30, 2010TE:ABRLD:Yes
Patent:⤷  Sign UpPatent Expiration:Aug 7, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATING OPIOID USE DISORDER
Patent:⤷  Sign UpPatent Expiration:Mar 26, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
Patent:⤷  Sign UpPatent Expiration:Apr 3, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION

Expired US Patents for NDA 022410

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Indivior SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-004 Aug 10, 2012 ⤷  Sign Up ⤷  Sign Up
Indivior SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-002 Aug 30, 2010 ⤷  Sign Up ⤷  Sign Up
Indivior SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 ⤷  Sign Up ⤷  Sign Up
Indivior SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-003 Aug 10, 2012 ⤷  Sign Up ⤷  Sign Up
Indivior SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 ⤷  Sign Up ⤷  Sign Up
Indivior SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.